Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Prevention of Scarring in Experimental Pyelonephritis in the Rat by Early Antibiotic Therapy

      ,

      Nephron

      S. Karger AG

      Kidney scarring, Pyelonephritis, Antibiotic therapy

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Experimental pyelonephritis was produced by either retrograde or direct infection of rat kidneys by Escherichia coli 078. Combined antibiotic therapy with amoxycillin and gentamicin, commenced within 23 h of direct infection, prevented acute suppuration and subsequent scarring. The same antibiotic combination commenced 24 h after both retrograde and direct infection did not significantly reduce acute suppuration but did reduce scarring. Treatment begun later than 24 h after infection had no effect on the outcome of pyelonephritis induced by either route. Significantly lower peak levels of serum antibody to the·antigen of E. coli O78 were obtained in rats treated at 24 h after retrograde pyelonephritis than in those in which treatment was started later. Kidney scarring could not be prevented if antibiotic therapy was commenced after the appearance of mononuclear cells in the inflammatory lesion.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1982
          1982
          03 December 2008
          : 30
          : 3
          : 262-268
          Affiliations
          K. R. U. F. Institute of Renal Disease, Welsh National School of Medicine, Cardiff Royal Infirmary, Cardiff, Great Britain
          Article
          182484 Nephron 1982;30:262–268
          10.1159/000182484
          7099339
          © 1982 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Original Paper

          Cardiovascular Medicine, Nephrology

          Antibiotic therapy, Pyelonephritis, Kidney scarring

          Comments

          Comment on this article